The long-term survival and the risks and benefits of implantable cardioverter defibrillators in patients with hypertrophic cardiomyopathy

Heart

Volumn 98, Issue 2, 2012, Pages 116-125

  O'Mahony, Constantinos ^a   Lambiase, Pier D ^a   Quarta, Giovanni ^a   Cardona, Montserrat ^a   Calcagnino, Margherita ^a   Tsovolas, Konstantinos ^a   Al Shaikh, Shereen ^a   Rahman, Shafiqur M ^a   Arnous, Samer ^a   Jones, Sue ^b   McKenna, William ^a   Elliott, Perry ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; WARFARIN;

ADULT; ARTERY EMBOLISM; ARTICLE; BACTERIAL ENDOCARDITIS; CARDIAC RESYNCHRONIZATION THERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DEFIBRILLATOR; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; FOLLOW UP; HEART DEATH; HEART TAMPONADE; HEART TRANSPLANTATION; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERICARDIAL EFFUSION; PERICARDITIS; PNEUMOTHORAX; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SKIN INJURY; SURVIVAL RATE; TRICUSPID VALVE REGURGITATION; UPPER EXTREMITY DEEP VEIN THROMBOSIS; WOUND INFECTION;

ADULT; AGED; CARDIOMYOPATHY, HYPERTROPHIC; DEFIBRILLATORS, IMPLANTABLE; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84155165452     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2010.217182     Document Type: Article

References (44)

1. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. Eur Heart J 2003;24:1965-91. (Pubitemid 37336422)
2. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008;117:e350-408. (Pubitemid 351771339)
3. Christiaans I, van Engelen K, van Langen IM, et al. Risk stratification for sudden cardiac death in hypertrophic cardiomyopathy: systematic review of clinical risk markers. Europace 2010;12:313-21.
4. Begley DA, Mohiddin SA, Tripodi D, et al. Efficacy of implantable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac death in hypertrophic cardiomyopathy. Pacing Clin Electrophysiol 2003;26:1887-96. (Pubitemid 37130061)
5. Jayatilleke I, Doolan A, Ingles J, et al. Long-term follow-up of implantable cardioverter defibrillator therapy for hypertrophic cardiomyopathy. Am J Cardiol 2004;93:1192-4. (Pubitemid 38521061)
6. Lin G, Nishimura RA, Gersh BJ, et al. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy. Heart 2009;95:709-14.
7. Maron BJ, Shen WK, Link MS, et al. Efficacy of implantable cardioverterd-fibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73. (Pubitemid 30084534)
8. Maron BJ, Spirito P, Shen WK, et al. Implantable cardioverter- defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:405-12. (Pubitemid 47124061)
9. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter-defibrillator. J Am Coll Cardiol 1998;31:1081-5.
10. Woo A, Monakier D, Harris L, et al. Determinants of implantable defibrillator discharges in high-risk patients with hypertrophic cardiomyopathy. Heart 2007;93:1044-5. (Pubitemid 47310979)
11. Kaski PJ, Tome Esteban MT, Lowe M, et al. Outcomes after implantable cardioverter-defibrillator treatment in children with hypertrophic cardiomyopathy. Heart 2007;93:372-4. (Pubitemid 46579536)
12. Marin F, Gimeno JR, Paya E, et al. The implantable cardioverter- defibrillator and hypertrophic cardiomyopathy. Experience at three centers. Rev Esp Cardiol 2006;59:537-44. (Pubitemid 44203197)
13. Syska P, Przybylski A, Chojnowska L, et al. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up. J Cardiovasc Electrophysiol 2010;21:883-9.
14. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
15. Sherrid MV, Daubert JP. Risks and challenges of implantable cardioverterd-fibrillators in young adults. Prog Cardiovasc Dis 2008;51:237-63.
16. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2. (Pubitemid 26074816)
17. McKenna WJ, Spirito P, Desnos M, et al. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Heart 1997;77:130-2. (Pubitemid 27115795)
18. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-18.
19. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18:1440-63. (Pubitemid 41821197)
20. Steyerberg EW. Clinical Prediction Models. A Practical Approach to Development, Validation and Updating. 1st edn. New York: Springer Science+Business Media, 2009.
21. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. 1st edn. New York, USA: Springer, 2001.
22. Maron BJ, Haas TS, Shannon KM, et al. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy. Heart Rhythm 2009;6:993-7.
23. Biagini E, Coccolo F, Ferlito M, et al. Dilated-hypokinetic evolution of hypertrophic cardiomyopathy: prevalence, incidence, risk factors, and prognostic implications in pediatric and adult patients. J Am Coll Cardiol 2005;46:1543-50. (Pubitemid 41446193)
24. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:216-25. (Pubitemid 44297115)
25. Melacini P, Basso C, Angelini A, et al. Clinicopathologicalprofiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010;31:2111-23.
26. Thaman R, Gimeno JR, Murphy RT, et al. Prevalence and clinical significance of systolic impairment in hypertrophic cardiomyopathy. Heart 2005;91:920-5. (Pubitemid 40874082)
27. Olivotto I, Maron BJ, Appelbaum E, et al. Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. Am J Cardiol 2010;106:261-7.
28. Olivotto I, Cecchi F, Gistri R, et al. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy. J Am Coll Cardiol 2006;47:1043-8.
29. Ho CY, Lopez B, Coelho-Filho OR, et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:552-63.
30. Rogers DP, Marazia S, Chow AW, et al. Effect of biventricular pacing on symptoms and cardiac remodelling in patients with end-stage hypertrophic cardiomyopathy. Eur J Heart Fail 2008;10:507-13.
31. Lee DS, Krahn AD, Healey JS, et al. Evaluation of early complications related to de novo cardioverter defibrillator implantation insights from the Ontario ICD database. J Am Coll Cardiol 2010;55:774-82.
32. Germano JJ, Reynolds M, Essebag V, et al. Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic? Am J Cardiol 2006;97:1255-61.
33. Galve E, Sambola A, Saldana G, et al. Late benefits of dual-chamber pacing in obstructive hypertrophic cardiomyopathy: a 10-year follow-up study. Heart 2010;96:352-6.
34. Ommen SR, Nishimura RA, Squires RW, et al. Comparison of dual-chamber pacing versus septal myectomy for the treatment of patients with hypertrophic obstructive cardiomyopathy: a comparison of objective hemodynamic and exercise end points. J Am Coll Cardiol 1999;34:191-6.
35. Dimitrow PP, Chojnowska L, Rudzinski T, et al. Sudden death in hypertrophic cardiomyopathy: old risk factors re-assessed in a new model of maximalized follow-up. Eur Heart J 2010;31:3084-93.
36. Elliott PM, Gimeno B Jr, Mahon NG, et al. Relation between severity of leftventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4. (Pubitemid 32156140)
37. Elliott PM, Gimeno JR, Tome MT, et al. Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy. Eur Heart J 2006;27:1933-41. (Pubitemid 44297366)
38. Connolly SJ. Use and misuse of surrogate outcomes in arrhythmia trials. Circulation 2006;113:764-6.
39. Nashef SA, Roques F, Michel P, et al. European System for Cardiac Operative Risk Evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999;16:9-13. (Pubitemid 29336425)
40. Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. J Am Coll Cardiol 2009;54:201-11.
41. Saumarez RC, Pytkowski M, Sterlinski M, et al. Paced ventricular electrogram fractionation predicts sudden cardiac death in hypertrophic cardiomyopathy. Eur Heart J 2008;29:1653-61. (Pubitemid 351957538)
42. O'Hanlon R, Grasso A, Roughton M, et al. Prognostic significance of myocardial fibrosis in hypertrophic cardiomyopathy. J Am Coll Cardiol 2010;56:867-74.
43. Shah JS, Esteban MT, Thaman R, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart 2008;94:1288-94.
44. Lewin RJ, Coulton S, Frizelle DJ, et al. A brief cognitive behavioural preimplantation and rehabilitation programme for patients receiving an implantable cardioverterd-fibrillator improves physical health and reduces psychologicalmorbidity and unplanned readmissions. Heart 2009;95:63-9.